-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The development of new drugs has always been characterized by high risk, difficulty, high cost and time-consuming
.
Therefore, in the context of the continuous improvement and development of artificial intelligence (AI) technology, more and more pharmaceutical companies have begun to use AI technology to deploy new drug research and development, shorten the research and development cycle, save compound screening costs and clinical trial costs, and improve the success of drug research and development.
rate
.
Looking at the world, a large number of domestic and foreign companies, including Novartis, Pfizer, GSK, AstraZeneca, Sanofi, Fosun Pharma, Qihui Bio, etc.
, have already tested the water layout of AI research and development of new drugs, and are in the AI pharmacy track.
.
Among them, Fosun Pharma has made frequent moves this year
.
On January 11 this year, after Fosun Pharma and Insilicon announced their "marriage", on February 17, the two parties announced that they had nominated the preclinical candidate compound ISM004-1057D for the cooperation project for new tumor immunotherapy
.
It is worth noting that Insilicon recently announced that it has used its self-developed artificial intelligence platform to nominate preclinical candidate compounds targeting QPCTL for innovative tumor immunotherapy
.
It is understood that this drug is also an important milestone in the strategic cooperation between Insilicon and Fosun Pharma
.
At present, the two parties are jointly conducting research for new drug clinical trial applications to advance the project to the clinical trial stage as soon as possible
.
On the whole, the current domestic AI pharmaceutical track is very hot.
Since this year, many local pharmaceutical companies have begun to actively deploy in the field of AI pharmaceuticals
.
In addition to Fosun Pharma, at the end of January this year, Qihui Bio and Unknown Jun jointly announced a strategic cooperation.
The two parties will integrate their respective technology and platform advantages to carry out in-depth development in the fields of intestinal flora extraction, purification, clinical application and AI pharmaceuticals.
Cooperation, and strive to promote the standardized quality control and supervision of China's intestinal flora extraction technology and microecological clinical preparation technology, and promote the orderly, benign and healthy development of the intestinal microecological industry
.
Prior to this, Xinhua Biotech, an AI-driven macromolecule drug research and development company, also announced that the company has completed a 100 million yuan financing led by Matrix Partners China and co-invested by Sequoia China and the company's existing investor Danlu Capital.
.
After the completion of this round of financing, the company will accelerate the research and development of AI-driven macromolecular drugs
.
It is worth mentioning that in addition to pharmaceutical companies, many domestic Internet technology companies are also accelerating their deployment, including Huawei's establishment of a medical intelligence "EIHealth", Alibaba Cloud's cooperation with the Global Health Drug Research and Development Center, and Tencent's establishment of AI-driven drug research and development.
The platform "Yunshen Zhiyao", Baidu established Baitu Biotechnology, ByteDance established a department dedicated to big health business,
etc.
In general, domestic AI pharmaceuticals are hot, and will continue to make great strides in 2022 under the pursuit of capital
.
Affected by this, drug research and development innovation is expected to continue to accelerate, and with the continuous emergence of innovative results, patients will have more choices in treatment in the future
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Therefore, in the context of the continuous improvement and development of artificial intelligence (AI) technology, more and more pharmaceutical companies have begun to use AI technology to deploy new drug research and development, shorten the research and development cycle, save compound screening costs and clinical trial costs, and improve the success of drug research and development.
rate
.
Looking at the world, a large number of domestic and foreign companies, including Novartis, Pfizer, GSK, AstraZeneca, Sanofi, Fosun Pharma, Qihui Bio, etc.
, have already tested the water layout of AI research and development of new drugs, and are in the AI pharmacy track.
.
Among them, Fosun Pharma has made frequent moves this year
.
On January 11 this year, after Fosun Pharma and Insilicon announced their "marriage", on February 17, the two parties announced that they had nominated the preclinical candidate compound ISM004-1057D for the cooperation project for new tumor immunotherapy
.
It is worth noting that Insilicon recently announced that it has used its self-developed artificial intelligence platform to nominate preclinical candidate compounds targeting QPCTL for innovative tumor immunotherapy
.
It is understood that this drug is also an important milestone in the strategic cooperation between Insilicon and Fosun Pharma
.
At present, the two parties are jointly conducting research for new drug clinical trial applications to advance the project to the clinical trial stage as soon as possible
.
On the whole, the current domestic AI pharmaceutical track is very hot.
Since this year, many local pharmaceutical companies have begun to actively deploy in the field of AI pharmaceuticals
.
In addition to Fosun Pharma, at the end of January this year, Qihui Bio and Unknown Jun jointly announced a strategic cooperation.
The two parties will integrate their respective technology and platform advantages to carry out in-depth development in the fields of intestinal flora extraction, purification, clinical application and AI pharmaceuticals.
Cooperation, and strive to promote the standardized quality control and supervision of China's intestinal flora extraction technology and microecological clinical preparation technology, and promote the orderly, benign and healthy development of the intestinal microecological industry
.
Prior to this, Xinhua Biotech, an AI-driven macromolecule drug research and development company, also announced that the company has completed a 100 million yuan financing led by Matrix Partners China and co-invested by Sequoia China and the company's existing investor Danlu Capital.
.
After the completion of this round of financing, the company will accelerate the research and development of AI-driven macromolecular drugs
.
It is worth mentioning that in addition to pharmaceutical companies, many domestic Internet technology companies are also accelerating their deployment, including Huawei's establishment of a medical intelligence "EIHealth", Alibaba Cloud's cooperation with the Global Health Drug Research and Development Center, and Tencent's establishment of AI-driven drug research and development.
The platform "Yunshen Zhiyao", Baidu established Baitu Biotechnology, ByteDance established a department dedicated to big health business,
etc.
In general, domestic AI pharmaceuticals are hot, and will continue to make great strides in 2022 under the pursuit of capital
.
Affected by this, drug research and development innovation is expected to continue to accelerate, and with the continuous emergence of innovative results, patients will have more choices in treatment in the future
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
